Neuromuscular diseases (NMDs) are chronic and so far incurable conditions that gradually affect patients’ muscles, leading to potentially severe disabilities. Biomedical researchers are busy looking for the diseases’ Achilles’ heel.
Original Source of Tracking down neuromuscular diseases
Sanofi-Aventis ( NYSE: SNY )
Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®[1], in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA).
Original Source of Sandoz leads the way with first generic version of ‘gold standard’ anti-thrombotic Lovenox®
Forest Laboratories and Merck KGaA said Thursday they have settled a patent lawsuit with companies they sued over the drug Alzheimer’s drug Namenda, granting 10 generics makers licenses to produce the drug in 2015. Report
Original Source of Forest settles Namenda patent fight with licenses
The FDA needs some time to think about Avandia safety–and apparently so do European regulators. This week the European Medicines Agency was expected to entertain recommendations on future use of the controversial GlaxoSmithKline diabetes drug. But the EMA Committee for Medicinal Products for Human Use (CHMP) said it needs…
Sanofi-Aventis sales reps have won a settlement in their gender bias case against the company, but it’s a small fraction of the big Novartis deal announced last week. One-tenth of the size, to be exact. Lawyers for the 5,200 current and former Sanofi reps asked a judge to approve…
Regulators in the European Union aren’t impressed with Provigil as a multipurpose wakefulness remedy. The European Medicines Agency has recommended new restrictions on the use of the Cephalon drug. Provigil should be used only to treat narcolepsy, the regulators say, because the benefits for other indications may not be…
In its first move to settle some of its Seroquel liability suits, AstraZeneca
The Federal Trade Commission is fighting back against allegations that it overstepped its bounds in investigating a “pay-for-delay” deal between Cephalon ( NASDAQ: CEPH ) and Watson Pharmceuticals ( NYSE: WPI ). The agency not only denied that it shared confidential information on Watson with generic rival Apotex, it’s…